Evidence map›Paper›PMID 41497979›Full record

ArticleFrontiers in immunology2025

Human tolerogenic dendritic cell subtypes exert divergent effects on induction of cytotoxic CD4

Gabrielle Barran, Najib Naamane, Abdul Mannan Baru, Amy E Anderson, Jane Falconer, Catharien M U Hilkens

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gabrielle BarranTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Najib NaamaneTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Abdul Mannan BaruImmunology Network, Immunology Research Unit, GlaxoSmithKline, Stevenage, United Kingdom.
Amy E AndersonTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Jane Falconer *John Dawson Drug Discovery and Development Institute, University of Sunderland, Sunderland, United Kingdom.
Catharien M U Hilkens *Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tolerogenic dendritic cells (tolDC) are currently in clinical trials for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The methods for producing therapeutic tolDC vary widely, with little being known about the commonalities and differences of distinct cell products in terms of their regulatory actions on CD4

Indexed as

CD4-Positive T-LymphocytesDendritic CellsImmune ToleranceT-Lymphocytes, CytotoxicArthritis, RheumatoidCells, CulturedCholecalciferolCoculture TechniquesDexamethasoneHLA-DR AntigensHumansLymphocyte ActivationCholecalciferolDexamethasoneHLA-DR Antigensautoimmune diseasescytotoxic CD4+ T cellsdexamethasonerheumatoid arthritistolerogenic dendritic cellsvitamin D3

Identifiers

PMID41497979
PMCPMC12765710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.